Indigestion — medically termed dyspepsia — is one of the most common reasons adults visit a primary care physician, affecting an estimated 25 to 40 percent of the global adult population at some point. Despite its prevalence, it is frequently misunderstood. Many adults use “indigestion” and “heartburn” interchangeably, but they are not the same: indigestion refers to upper abdominal discomfort centered in the epigastric region (below the breastbone, above the navel), while heartburn is a burning sensation in the chest caused by acid reflux into the esophagus. The two can occur together, but managing each requires understanding which is present. For related context on how these digestive symptoms connect, see common digestive problems in adults.
What Indigestion Feels Like
Indigestion symptoms are defined by their location (upper abdomen) and character. The Rome IV criteria for functional dyspepsia — the version without a structural explanation — require one or more of the following: postprandial fullness (an uncomfortable sensation that food lingers longer than expected after eating), early satiety (feeling full after eating only a small amount of food, preventing finishing a normal-sized meal), epigastric pain (pain in the upper central abdomen), or epigastric burning (a burning sensation in the upper abdomen, distinct from the chest burning of heartburn). These symptoms must be present for at least 3 months, with onset at least 6 months prior, and without a structural cause identified on investigation.
The Rome IV classification divides functional dyspepsia into two subtypes that reflect different underlying mechanisms. Postprandial distress syndrome (PDS) is dominated by meal-triggered symptoms — postprandial fullness, early satiety, nausea with eating, and sometimes bloating in the upper abdomen. It reflects impaired gastric accommodation (the stomach’s ability to relax and expand with a meal) and delayed gastric emptying. Epigastric pain syndrome (EPS) is characterized by pain or burning in the upper abdomen that may or may not be related to eating and may be transiently relieved by food or antacids. It reflects visceral hypersensitivity — the stomach interprets normal intragastric pressure or acid as painful. Both subtypes can occur in the same patient, though one typically predominates. Recognizing which pattern applies is clinically useful because treatments differ: prokinetics are more relevant to PDS, while acid-suppressive therapy has more evidence for EPS.
Common Causes of Indigestion
Indigestion has a range of causes from dietary and lifestyle to functional GI disorders to structural disease. The largest single category is functional dyspepsia — indigestion without an identifiable structural cause on endoscopy, representing approximately 10 to 15 percent of the general adult population. The mechanisms behind functional dyspepsia include delayed gastric emptying (in approximately 30 to 40 percent of patients), impaired gastric accommodation, visceral hypersensitivity (the stomach perceives normal distension as painful), and gut-brain dysregulation through the vagal and autonomic nervous systems.
H. pylori infection is present in approximately 44 percent of the global adult population and is the most important identifiable cause of non-structural indigestion. H. pylori colonizes the gastric mucosa, produces urease that neutralizes stomach acid locally, and provokes an inflammatory response. Not all adults with H. pylori develop symptoms — only about 20 to 25 percent develop clinically significant dyspepsia — but eradicating H. pylori in symptomatic infected patients produces clinically meaningful symptom improvement in a substantial proportion and eliminates the risk of peptic ulcer disease and gastric cancer associated with chronic H. pylori colonization. NSAIDs (non-steroidal anti-inflammatory drugs) — including ibuprofen, naproxen, and aspirin — are a major and underappreciated cause of indigestion. NSAIDs inhibit cyclooxygenase (COX) enzymes, which are required for prostaglandin synthesis. Prostaglandins protect the gastric mucosa by stimulating mucus and bicarbonate secretion and maintaining mucosal blood flow. NSAIDs reduce this protection, making the mucosa vulnerable to acid-related injury. This produces gastritis, gastric erosions, and peptic ulcers — and associated indigestion symptoms — in a clinically significant proportion of regular NSAID users. Adults who take NSAIDs regularly and develop upper GI symptoms should discuss switching to acetaminophen (where feasible for their pain indication), adding a proton pump inhibitor, or taking NSAIDs with food. The NIDDK indigestion overview covers the full range of causes and diagnostic approaches. Dietary and lifestyle factors are among the most modifiable. Fatty foods slow gastric emptying and increase intragastric pressure, worsening postprandial fullness. Spicy foods stimulate TRPV1 receptors in the stomach, which can trigger pain and burning in viscerally hypersensitive individuals. Alcohol irritates the gastric mucosa directly. Eating large volumes quickly overwhelms gastric accommodation. Smoking impairs lower esophageal sphincter function and delays gastric emptying. High chronic stress levels activate the hypothalamic-pituitary-adrenal axis and autonomic nervous system in ways that alter gut motility and visceral sensitivity — explaining why stress is a consistent trigger for indigestion episodes in patients with functional dyspepsia. For context on related symptom patterns, see bloating: common causes and when to seek care and gas and digestive health.
Structural Causes of Indigestion
When indigestion is caused by an identifiable structural abnormality, it is classified as organic dyspepsia. The most important structural causes are:
Peptic ulcer disease — ulcers in the gastric or duodenal mucosa — produces epigastric pain that is often described as gnawing or burning and that has a characteristic relationship to food: gastric ulcer pain typically worsens with eating, while duodenal ulcer pain often improves with food and worsens when the stomach is empty (particularly at night). H. pylori and NSAIDs together account for the large majority of peptic ulcers. Gastritis — inflammation of the stomach lining — produces upper abdominal discomfort, nausea, and sometimes vomiting. The most common causes are H. pylori, NSAID use, excessive alcohol, and autoimmune gastritis (pernicious anemia). Chronic atrophic gastritis from H. pylori or autoimmune disease increases the risk of gastric cancer over time. Gastroparesis — delayed gastric emptying — produces a feeling of persistent fullness and nausea that begins during or shortly after a meal and continues for hours. It is associated with diabetes, prior viral illness, and post-surgical anatomy. Gallbladder disease, including biliary dyskinesia (impaired gallbladder emptying) and gallstones, can produce upper abdominal symptoms that overlap with indigestion — typically postprandial, often worse with fatty meals, and sometimes accompanied by right upper quadrant pain. Gallbladder disease may not be apparent on standard upper GI evaluation; abdominal ultrasound is the first-line imaging for suspected biliary pathology.
Alarm Symptoms Requiring Prompt Evaluation
Indigestion in most adults is benign and manageable. However, certain features change the evaluation timeline from routine to urgent and should prompt immediate medical evaluation rather than empiric self-treatment. Age 55 or older with new-onset indigestion (American College of Gastroenterology guideline) warrants prompt upper endoscopy to evaluate for gastric cancer, which has a rising incidence and is often asymptomatic in early stages. This threshold is slightly different from some international guidelines (European: 55, NICE UK: 55), reflecting the evidence base for early endoscopy detection. Unintentional weight loss accompanying indigestion — particularly 5 percent or more of body weight over 6 to 12 months — is a red flag for malignancy that must be evaluated promptly. Dysphagia (difficulty swallowing) with indigestion suggests esophageal pathology — stricture, malignancy, or motility disorder — requiring upper endoscopy. Persistent or forceful vomiting that does not resolve with dietary changes is a structural alarm sign. GI bleeding — vomiting blood (hematemesis, “coffee-ground” emesis) or black tarry stools (melena) — indicates active upper GI bleeding and requires emergency evaluation. Palpable epigastric mass on physical examination must be investigated. Family history of upper GI cancer (gastric, esophageal) in a first-degree relative lowers the threshold for early endoscopy. The ACG dyspepsia guidelines provide the clinical framework for when alarm features mandate immediate investigation versus empiric management.
H. pylori and Indigestion — The Test-and-Treat Approach
The ACG recommends a “test-and-treat” strategy for H. pylori in adults with uninvestigated dyspepsia in regions where H. pylori prevalence exceeds 10 percent — which includes the United States. In this approach, patients with new-onset indigestion without alarm features are tested for H. pylori (using a urea breath test or stool antigen test — both of which are accurate, non-invasive, and do not require endoscopy) before any empiric acid suppression is started. If H. pylori-positive, the patient is treated with eradication therapy (typically triple or quadruple antibiotic regimens for 10 to 14 days) and retested at 4 weeks after treatment to confirm eradication. If H. pylori-negative, empiric acid suppression with a PPI or H2 blocker is appropriate as first-line treatment.
The rationale for testing before treating with acid suppression is important: PPIs suppress H. pylori growth, which can produce false-negative test results if the patient has been taking a PPI recently. Testing should be done after stopping PPIs for at least 2 weeks and antibiotics for at least 4 weeks. Eradicating H. pylori in H. pylori-positive dyspepsia patients produces symptom resolution or significant improvement in approximately 8 to 10 percent more patients than placebo at 12 months — a modest but clinically meaningful benefit — and also eliminates long-term cancer risk associated with H. pylori colonization that acid suppression alone does not address.
Relief Options — What Works for Indigestion
Dietary modification is the most sustainable first-line approach for functional dyspepsia. Identifying personal trigger foods — fatty and fried foods, spicy foods, caffeine, carbonated drinks, alcohol — through a food and symptom diary, and reducing intake of confirmed triggers, often produces meaningful symptom improvement within 2 to 4 weeks without medication. Smaller, more frequent meals reduce the gastric volume at any one time, which is particularly helpful for the postprandial fullness and early satiety of the PDS subtype. Eating slowly and chewing thoroughly reduces the stimulus to gastric distension. Antacids (calcium carbonate, aluminum/magnesium hydroxide) provide rapid but brief relief by neutralizing gastric acid. They are appropriate for occasional indigestion episodes but are not a treatment for chronic indigestion because they do not address the underlying cause and their repeated use can cause side effects (rebound acid with calcium carbonate, diarrhea with magnesium-containing products, constipation with aluminum-containing products). H2 receptor antagonists (famotidine, cimetidine) reduce acid secretion by blocking histamine H2 receptors on parietal cells. They are effective for both indigestion and heartburn, with an onset of action slower than antacids (30 to 60 minutes) but a duration of 6 to 12 hours. H2 blockers have a good safety profile and are appropriate for both acute and short-term chronic use. Proton pump inhibitors (PPIs) are the most potent acid-suppressive agents and are the preferred treatment for organic dyspepsia from GERD or peptic ulcer disease. For functional dyspepsia (H. pylori-negative, EPS subtype), PPIs provide modest benefit above placebo. They are not the preferred treatment for the PDS (postprandial distress) subtype, which is dominated by motility rather than acid issues. Long-term PPI use requires monitoring for potential effects on magnesium and B12 absorption and bone density with extended use. Prokinetics (metoclopramide, domperidone) accelerate gastric emptying and reduce postprandial fullness and nausea — making them more relevant to the PDS subtype of functional dyspepsia and gastroparesis. Low-dose tricyclic antidepressants (amitriptyline, nortriptyline at doses of 10 to 25 mg) have consistent evidence for reducing visceral pain in functional dyspepsia by modulating pain signaling in the gut-brain axis. They are used at doses much lower than those used for depression and have a different mechanism of action in the GI tract. For patients with chronic functional dyspepsia that has not responded to dietary and acid-suppressive approaches, low-dose TCAs are a consideration worth discussing with a gastroenterologist. For reference on the lab values and screening benchmarks relevant to the broader GI picture, see liver and digestive health numbers every adult should know.
Frequently Asked Questions
What is the difference between indigestion and heartburn?
Indigestion (dyspepsia) refers to discomfort or pain centered in the upper abdomen (epigastric region) — including postprandial fullness, early satiety, and epigastric burning or pain. Heartburn is a burning sensation in the chest caused by acid refluxing up into the esophagus. They can occur together (acid reflux can cause both), but indigestion is not simply another word for heartburn. Many causes of indigestion — functional dyspepsia, H. pylori, gastroparesis — do not produce heartburn at all.
How do I know if I have H. pylori?
H. pylori infection often produces no symptoms at all. When it does cause symptoms, they are indistinguishable from other causes of indigestion — upper abdominal discomfort, nausea, bloating. The diagnosis requires testing: a urea breath test or stool antigen test are the most accurate non-invasive options. Neither requires endoscopy. If you have indigestion and have not been tested for H. pylori, discussing this with your physician is a reasonable first step — particularly if you have not responded to dietary changes or antacids.
Can ibuprofen cause indigestion?
Yes. NSAIDs including ibuprofen, naproxen, and aspirin reduce the production of prostaglandins that protect the stomach lining from acid, making the mucosa vulnerable to inflammation and ulceration. Regular NSAID use is one of the most common causes of indigestion, gastritis, and peptic ulcer disease. Taking NSAIDs with food reduces but does not eliminate this risk. Adults who need regular NSAID use for pain or cardiovascular protection and who develop upper GI symptoms should discuss adding a PPI, switching to acetaminophen where appropriate, or using a COX-2 selective NSAID (which has somewhat less GI toxicity) with their physician.
When should indigestion be evaluated by a doctor?
Occasional indigestion after a large or unusually rich meal does not require evaluation. Indigestion that is persistent (occurring several times per week), not responding to over-the-counter treatments, accompanied by weight loss or difficulty swallowing, or beginning after age 55 should be evaluated by a clinician. Any indigestion accompanied by vomiting blood, black tarry stools, or a palpable abdominal mass requires urgent medical evaluation. The Mayo Clinic’s indigestion overview provides practical guidance on when self-care is appropriate versus when evaluation is needed.
Is functional dyspepsia a permanent condition?
Not necessarily. Functional dyspepsia has a variable course — some patients have episodic symptoms that come and go with stress or dietary patterns, while others have persistent symptoms. Studies following patients over years show that approximately one-third experience symptom resolution, one-third remain stable, and one-third experience fluctuating improvement and worsening. Identifying and managing triggers (dietary, stress-related, NSAID use) produces significant improvement in many patients. For those with persistent symptoms despite first-line treatment, specialist evaluation to identify the dominant mechanism (delayed emptying vs. visceral hypersensitivity) and tailor treatment accordingly typically improves outcomes.
Sources: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American College of Gastroenterology (ACG) Dyspepsia Guidelines; American Gastroenterological Association (AGA); Rome IV Criteria for Functional GI Disorders; Mayo Clinic; Cochrane Reviews on H. pylori and Dyspepsia.
Managing Functional Dyspepsia Long-Term
For adults with chronic functional dyspepsia, management is iterative rather than one-and-done. Because no single treatment reliably works for all patients, a systematic approach — starting with the most modifiable factors and adding targeted interventions based on which subtype predominates — produces better outcomes than empiric treatment without a working diagnosis.
The first step for most adults is identifying and addressing modifiable triggers. A food and symptom diary kept for 2 to 4 weeks documents which foods, meal sizes, eating speeds, and stress levels correlate with symptom onset. This often reveals patterns that were not apparent from memory — many patients discover that meal size is a stronger trigger than any specific food, or that symptoms are predominantly stress-triggered rather than diet-triggered. This information changes the treatment approach: meal size and eating pace require behavioral modification, while stress-triggered dyspepsia may benefit more from gut-directed hypnotherapy, CBT, or low-dose neuromodulator treatment than from dietary restriction.
H. pylori status should be established before starting acid-suppressive therapy, both because H. pylori testing is less accurate after PPI exposure and because identifying and eradicating H. pylori can produce durable symptom improvement that medication alone does not. Once H. pylori status is confirmed negative and structural disease has been excluded (by endoscopy if alarm features are present or age warrants it), treatment can be targeted to the predominant subtype. PDS (postprandial distress) responds better to prokinetics, dietary modification, and buspirone (a 5-HT1A agonist that improves gastric accommodation) than to PPIs alone. EPS (epigastric pain syndrome) responds to PPIs and H2 blockers, and low-dose TCAs when acid suppression alone is insufficient.
Stress management is an underutilized component of functional dyspepsia treatment. The gut-brain axis is not a metaphor — it is an anatomically real bidirectional communication system, and the evidence for psychological interventions in functional GI disorders is substantial. Cognitive behavioral therapy (CBT) specifically adapted for functional GI disorders has randomized trial evidence for functional dyspepsia, producing improvements comparable to pharmacological approaches in chronic cases. Gut-directed hypnotherapy has even stronger evidence in IBS and preliminary evidence in functional dyspepsia. These approaches work through modulating central pain perception and autonomic tone — not by eliminating stress from the patient’s life, which is typically not possible, but by changing how the gut responds to it.
Adults managing indigestion alongside concerns about broader upper GI health should be aware that functional dyspepsia and organic disease can coexist — having confirmed functional dyspepsia does not prevent a later structural cause from developing, particularly with aging, NSAID use, or H. pylori acquisition. Annual review with a clinician is appropriate for adults with chronic functional dyspepsia to reassess whether alarm features have appeared and whether the current management approach is still appropriate. For context on the full picture of digestive health monitoring and what benchmarks to watch as adults age, see liver and digestive health numbers every adult should know and why liver and digestive health matter after age 40.
Indigestion is among the most common conditions in adult medicine, and yet it remains undertreated — not because treatments are unavailable, but because it is frequently managed empirically without identifying the cause. An adult who buys antacids for years without improvement is rarely getting the wrong product; they are usually getting the wrong diagnosis. Antacids treat acid, but most functional dyspepsia is not primarily an acid-volume problem. H. pylori goes untested for years in patients who would benefit from eradication. NSAIDs continue to be taken daily without a PPI in patients whose indigestion is NSAID-induced gastritis. Identifying which of these mechanisms is responsible — through a food diary, an H. pylori test, or a review of medications with a clinician — typically produces better outcomes than any single over-the-counter remedy taken indefinitely without that information. The combination of symptom pattern recognition (PDS vs. EPS vs. stress-triggered vs. structural) and targeted testing produces a management path that is both more effective and less expensive over time than empiric, revolving-door symptom suppression.
Adults who have managed indigestion for years without systematic evaluation often find that a single focused clinical encounter — history, H. pylori test, medication review — produces more improvement than years of trial-and-error self-management. The tools exist; the limiting factor is usually not accessing them early enough.
I had upper abdominal discomfort after nearly every meal for about two years. My primary care physician prescribed a PPI after a normal endoscopy — H. pylori negative, no ulcers, no significant findings. The PPI helped somewhat initially but the improvement plateau’d quickly and I was still having daily postprandial fullness and early satiety that made eating a miserable experience. Nobody ever mentioned the distinction between the two subtypes you describe here — postprandial distress syndrome versus epigastric pain syndrome. When I finally saw a GI specialist, she identified my pattern as clearly PDS-dominant and explained that PPIs are not the primary treatment for that subtype. She added buspirone off-label for gastric accommodation and a low-dose antidepressant, and within six weeks my ability to eat a full meal without stopping early had improved dramatically. The article’s explanation of why treatments differ by subtype is something I genuinely wish I had encountered earlier.
Gina, your experience accurately reflects the state of functional dyspepsia management in primary care: PDS-dominant dyspepsia is not primarily an acid-volume disorder, and PPIs therefore address only a part of the mechanism — specifically, any acid-related component of epigastric discomfort — while leaving the impaired gastric accommodation and delayed emptying that drive PDS largely unaddressed. Buspirone at 10 mg three times daily has randomized trial evidence specifically for improving gastric accommodation in functional dyspepsia, and the combination with a neuromodulator for visceral sensitivity represents current best practice for refractory PDS. Felix, the gastric ulcer complication rate with daily NSAID use is estimated at approximately 2 to 4 percent per year — lower than many patients assume, but substantial when multiplied across years of use. Co-prescribing a PPI with a daily NSAID reduces ulcer risk by approximately 60 to 80 percent. The ACG recommends PPI co-therapy for any patient taking regular NSAIDs with any of the following risk factors: age over 65, prior ulcer or GI bleeding history, or concomitant anticoagulant/antiplatelet use.
I took ibuprofen daily for knee osteoarthritis pain for approximately four years before a GI workup identified a gastric ulcer with surrounding gastritis. I was never told by the prescribing physician to take a stomach protectant, and nothing on the ibuprofen packaging mentioned the risk of ulceration with daily use in terms I connected to my own situation. The NSAID section of your article explains the mechanism clearly — prostaglandin inhibition removes the mucosa’s protective barrier — and makes the case for adding a PPI when daily NSAID use is unavoidable. I switched to a COX-2 selective NSAID with a daily PPI after the ulcer was treated, and I have not had a recurrence in three years. The practical note in your article about discussing alternatives with a physician when GI symptoms develop on NSAIDs is exactly the conversation that should have happened years before my ulcer.